bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%.
BIAF · bioAffinity Technologies, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at September 30, 2026, of $2.6 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Nov 6, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
bioAffinity Technologies reports a record 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, its highest monthly testing volume. October volume was equivalent to approximately 45% of tests performed in Q3 2026.
bioAffinity Technologies reported that CyPath Lung test unit sales increased 100% through Q3 2026, while third-quarter revenue fell to approximately $1.1 million and net loss widened to approximately $5.3 million from approximately $5.1 million.
bioAffinity Technologies reported a net loss of $12.3 million for the nine months ended September 30, 2026, and management concluded there is substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $2.6 million at September 30, 2026, and $4.6 million as of November 3, 2026, which the company expects will support operations through March 2027.
bioAffinity Technologies will join physicians, patients and healthcare providers at the Lung Cancer Initiative of North Carolina's Battle of the Blues on November 5, 2026. It will share CyPath Lung, a noninvasive lung cancer test, at the event.
bioAffinity Technologies will hold a special stockholder meeting on November 20, 2026, to vote on issuing up to 1,128,272 shares under August 2026 warrants and 980,072 shares under October 2026 warrants. Other proposals would seek authorization for non-public offerings and reduce authorized common stock from 350,000,000 shares to 200,000,000 shares. The Board recommends voting FOR all proposals.
bioAffinity Technologies will sponsor a CHEST 2026 Learning Theater presentation on October 21, 2026, covering CyPath Lung for pulmonary nodule management and lung cancer risk stratification, plus preliminary research on an investigational asthma and COPD inflammation test.
bioAffinity Technologies will present new data at CHEST 2026 on investigational sputum-based tests designed to characterize lung inflammation and detect protein biomarkers associated with asthma and COPD therapies; a poster is scheduled for October 20, 2026.
bioAffinity Technologies, Inc. closed an approximately $4 million offering on October 9, 2026, comprising 116,545 shares, pre-funded warrants for up to 536,836 shares, and warrants for up to 980,072 shares. Net proceeds are for working capital.
The Japan Patent Office issued a Notice of Allowance for bioAffinity Technologies covering a method of predicting lung cancer likelihood using the CyPath® Lung test; patent issuance is expected after payment of the applicable issuance fee.
bioAffinity Technologies reported that CyPath Lung sales increased more than 100% through the third quarter of 2026 versus 2025, ordering physicians rose 89% in Q3 2026, and more than 1620 tests were delivered versus 775.
bioAffinity Technologies and AvMEDICAL debuted the first joint exhibition of CyPath Lung to more than 300 physicians, healthcare professionals and VA leaders, intending to expand federal access to the noninvasive lung cancer test.
bioAffinity Technologies seeks approval to issue up to 1,128,272 common shares from August 2026 warrants, authorize non-public offerings of up to [10,000,000] shares for $[10,000,000] at discounts up to 35%, and reduce authorized common shares from 350,000,000 to [200,000,000].
bioAffinity Technologies will present two CyPath® Lung posters at the 2026 NAVREF Annual Conference, September 27-30, 2026, including data from an enrolling 2,000-patient veteran and military study.